Myelofibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)

Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK inhibitors ruxolitinib (Incyte), fedratinib (Bristol Myers Squibb), pacritinib (CTI BioPharma), and momelotinib (GSK) are the only drugs approved for myelofibrosis in the United States and EU5 (pacritinib only in the United States). Although JAK inhibitors are a therapeutic option, they do not address all myelofibrosis symptoms and are associated with high discontinuation rates. Thus, significant market opportunity remains for safe and tolerable treatments that can manage the full spectrum of myelofibrosis symptoms (reducing the need for polypharmacy) and that can treat patients with comorbid thrombocytopenia and anemia.

Questions answered

• What are the sizes of the U.S. and EU5 diagnosed prevalent and incident primary and secondary myelofibrosis populations? What are the distributions of risk level among diagnosed incident and prevalent cases of primary myelofibrosis?
• What is the current treatment landscape for myelofibrosis? What are physicians’ experience and satisfaction with current key therapies?
• How have ruxolitinib, fedratinib, pacritinib, and momelotinib been integrated into the myelofibrosis treatment algorithm? How will these drugs compete in the treatment of myelofibrosis?
• What are the key unmet needs and areas of commercial opportunity for myelofibrosis? How will novel therapies impact the treatment algorithm for myelofibrosis, and which myelofibrosis patients will be served by these treatment options in 2033?

Geography: United States and EU5.

Primary research: Five country-specific interviews with thought-leading hematologists. Supported by survey data collected for this study.

Epidemiology: Diagnosed incidence and prevalence of primary and secondary myelofibrosis by country, diagnosed incidence and prevalence of primary myelofibrosis by risk (DIPSS and IPSS, respectively), comorbidities, and biomarkers (JAK2 mutation, peripheral blasts > 1%, splenomegaly), with population-specific drug-treatment rates.

Forecast: Drug-level sales and patient share of key myelofibrosis therapies in 2023 and 2033.

Drug treatments: Coverage of key current and emerging therapies.

Product description: Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key feature: Niche & Rare Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations